New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
07:34 EDTARIAARIAD long-term risk/reward ratio compelling, says RBC Capital
RBC Capital believes that several upcoming events could enable ARIAD's stock to advance significantly more than bears expect. Such events include stronger than expected sales of the company's Iclusig drug and positive clinical results for its '113 lung cancer drug. The firm keeps a $28 price target and Outperform rating on the shares.
News For ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
07:36 EDTARIAARIAD, STA announce approval of Iclusig in Australia
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use